Webb31 aug. 2024 · Landmark clinical trials of DOACs in patients with AF systematically excluded these patient populations. However, there are trial data in both animals and humans regarding the use of DOACs in patients with MS and in those with mechanical heart valves. Summary Webb28 juni 2024 · The COMPASS trial, like many of the other landmark DOAC trials before it, enrolled few patients with morbid obesity (BMI ≥40 kg/m 2 ), though this subgroup now …
Cardiology – Landmark Trials
Webb6 dec. 2024 · A meta-analysis was performed on the landmark DOAC trials in 2014, including The Randomized Evaluation of Long-Term Anticoagulation Therapy, or RE-LY … Webb18 sep. 2014 · In the last 4 years, 6 phase 3 trials including a total of 27 023 patients with venous thromboembolism (VTE) compared a direct oral anticoagulant (DOAC) with vitamin K antagonists (VKAs). To aid the clinician in assessing the amount of information, we address frequently raised clinical questions in a review of combined trial results. いいものプレミアム 圧力鍋
The representativeness of direct oral anticoagulant clinical trials to ...
Webb20 juli 2024 · As the landmark DOAC trials excluded patients with CKD stage IV or greater, small retrospective cohorts such as ours may give insight into which OFXai may be preferred [5–11]. Out of the 17 patients in our OFXai arm, 14/17 were on apixaban, which is likely due to the limited renal clearance and benefit seen in patients with advanced … Webb7 apr. 2024 · The cutoff creatinine clearance of 30 mL/min utilized in the DOAC trials could also have influenced these results. Moreover, accumulating data clearly indicate that food and drug interactions, genetic variations, and phenotypic features can affect DOAC anticoagulation and can increase the bleeding risk in these patients [ 29 ]. Webb1 maj 2024 · On the basis of data from the landmark DOAC trials in AF, dose adjustment for each of the DOACs was approved by the FDA and accounts primarily for patient characteristics such as age, body weight, and renal function. However, off-label dosing of DOACs in patients with AF remains a common practice and involves both underdosing … いいものプレミアム 何時から